ASND Ascendis Pharma
Price Chart
Executive Summary
Ascendis Pharma announced positive Week 52 results from its Phase 2 New InsiGHTS trial, showing that once-weekly TransCon hGH achieved annualized height velocity (9.05 cm/year) comparable to daily somatropin (9.04 cm/year) in children with Turner syndrome, with a similar safety profile and no cases of slipped capital femoral epiphysis. The data support ongoing Phase 3 HighLiGHts trial efforts for potential label expansion into growth hormone sufficiency indications.
Actionable Insight
The comparable efficacy and favorable safety profile vs. daily therapy strengthens TransCon hGH’s differentiation as a once-weekly treatment, potentially driving adoption in Turner syndrome and supporting future label expansion. Traders should monitor progress in the Phase 3 HighLiGHts trial as a key catalyst.
Key Facts
- TransCon hGH demonstrated annualized height velocity of 9.05 cm/year (LS mean) at Week 52, vs. 9.04 cm/year for daily somatropin
- Trial included 49 prepubertal children with Turner syndrome aged 1–10 years
- No occurrences of slipped capital femoral epiphysis (SCFE) in TransCon hGH group
- Adverse events were mild to moderate; none led to discontinuation
- Mean weekly dose: 0.22 mg/kg for TransCon hGH vs. 0.29 mg/kg for daily somatropin
- Safety follow-up extended up to 143 weeks with comparable tolerability
- Phase 3 HighLiGHts basket trial is now underway to support label expansion
Financial Impact
Potential for expanded market share in pediatric growth disorders; supports premium pricing and reimbursement positioning for once-weekly TransCon hGH
Risk Factors
- Regulatory approval not guaranteed despite positive Phase 2 data
- Phase 3 trial may not replicate efficacy or safety findings
- Competition from existing and emerging growth hormone therapies
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257185 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
6-K
| $215.32 awaiting T+1 | awaiting T+1 | — | $218.06 (+1.27%) |
|
Jun 2, 2026
10d ago
|
Insider Cluster
| $216.79 $218.84 | ▲ +0.95% | ▲ +0.55% | $218.06 (+0.59%) |
|
May 19, 2026
24d ago
|
ANALYST-UPGRADE
| $237.98 $241.34 | ▲ +1.41% | ▲ +0.37% | $218.06 (−8.37%) |
|
May 16, 2026
27d ago
|
ANALYST-UPGRADE
| $170.74 $162.84 | ▼ −4.63% | ▼ −3.78% | $218.06 (+27.71%) |
|
May 7, 2026
5w ago
|
6-K
| $246.14 $238.66 | ▼ −3.04% | ▼ −3.87% | $218.06 (−11.41%) |
|
May 7, 2026
5w ago
|
6-K
| $246.14 $238.66 | ▼ −3.04% | ▼ −3.87% | $218.06 (−11.41%) |
|
May 6, 2026
5w ago
|
Press Release
| $246.14 $246.14 | · 0.00% | ▼ −0.83% | $218.06 (−11.41%) |
|
Apr 21, 2026
7w ago
|
6-K
| $240.29 $231.05 | ▼ −3.85% | ▼ −4.86% | $218.06 (−9.25%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $242.95 $244.48 | ▲ +0.63% | ▼ −0.58% | $218.06 (−10.24%) |
|
Apr 8, 2026
9w ago
|
6-K
| $241.71 $239.28 | ▼ −1.01% | ▼ −0.94% | $218.06 (−9.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access